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ABSTRACT OF THESIS

P53 AND REACTIVE OXYGEN SPECIES: A CONVOLUTED STORY
The tumor suppressor p53 has a close relation with reactive oxygen species (ROS).
As an indispensable component of the cellular redox system, ROS not only have been
established to be involved in p53-dependent apoptosis, but also regulate p53 activity.
Recent studies revealed several novel actions of p53, such as transactivation of
antioxidative proteins, mitochondria translocation and inhibition of glycolysis. The fate
of cells where p53 signaling pathways are initiated is either survival or death. In this
review, we examine the hypothesis that ROS regulate cell fate through p53, in a way that
physiological ROS levels trigger the protective pathways, while p53 behaves more like a
cell killer under cytotoxic oxidative stress.
KEYWORDS: p53, reactive oxygen species (ROS), cell fate, redox proteins,
mitochondria.
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I. Introduction

Reactive oxygen species (ROS) are highly reactive small molecules containing oxygen.
ROS include oxygen ions (such as hypochlorite ion, OCl−), free radicals (such as
hydroxyl radical, ·OH) and molecules (such as hydrogen peroxide, H2O2). ROS can be
formed upon external stimulation such as ionizing radiation and as natural byproducts of
cellular respiration. ROS are traditionally considered to damage DNA and to trigger
apoptosis, but positive roles of ROS, particularly as signaling molecules, are also well
documented in many areas of research, such as cancer, heart disease, neuroscience, and
many others (for recent reviews, see [1-12]).

The interaction between tumor suppressor protein p53 and ROS has been the subject of
many studies in recent years. It has been suggested that p53 and ROS affect each other,
leading to a cascade of downstream events. p53 is one of the most critical and extensively
studied regulators of cell fate. Once activated, p53 can lead to cell survival (either cell
cycle arrest or permanent arrest, also known as senescence) or apoptosis, depending on
the severity of damage and condition of the cells (for recent reviews, see [13-15]). More
and more evidence supports the hypothesis that intracellular ROS levels regulate cell fate
through p53. This article summarizes some research highlights of this issue, emphasizing
the response of p53 to ROS stimulation under different stress conditions and
corresponding events downstream of p53 activation.
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II. Backgrounds

II.A. Functions, structure and properties of p53

p53 deficiency, which results in failure to control cell proliferation, is generally
considered a significant genetic basis for cancer. It is estimated that functional mutation
of TP53, the gene encoding tumor suppressor p53, occurs in 50% of human cancers, but
this estimate may be far lower than actual incidence [16].

The human p53 gene (TP53) is located on the 17th chromosome (17p13.1) [17]. The p53
protein is a phosphoprotein consisting of 393 amino acids, with a molecular mass of 53
kDa, which gives the protein its name.

The p53 protein is made up of five domains. Localized at the N-terminus is the
transactivation (TA) domain (amino acids 1-50). The TA domain binds to several
components of the RNA transcription complex including the TATA-binding protein
(TBP) and TBP-associated factors (TAFs), which regulate the transactivation capacity of
p53 [18-21]. The ability to control transcription is essential to the role of p53 in inducting
cell cycle arrest as well as apoptosis [22-24]. Amino acids in the transactivation domain
are heavily phosphorylated upon radiation treatment, which is a sign of p53 activation.
For instance, Ser6, Ser9, Ser15, Thr18, Ser20, Ser33, Ser37 and Ser46 undergo this
modification [25]. Next to the transactivation domain is a polyproline domain (amino
acids 63-97) that is necessary for transcription-independent apoptotic and growth
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suppression functions [26-28]. There is a nuclear export signal (NES) in the N-terminus.
In the middle part of the p53 protein lies the core domain (amino acids 100-300) which is
responsible for the sequence-specific DNA binding activity of p53. Crucial to this
important p53 function are four evolutionarily conserved regions within this domain [29].
Amino acids in the four regions have been identified in over 90% of the mutations found
in human cancers [25]. Six amino acid residues that are essential to preserve the structure
of the DNA binding motifs are the most frequently mutated (175 Arg>His, 245 Gly>Ser,
248 Arg>Trp, 249 Arg>Ser, 273 Arg>His, and 282 Arg>Trp), and they are often referred
to as “hot-spot” mutations [25, 30]. A domain in the C-terminus (amino acids 323-356)
helps p53 protein molecules to form tetramers, the optimized form for p53 to achieve its
functions [31]. The C-terminus also plays an important part in the interaction of p53 with
non-specific double stranded DNA, single stranded DNA and damaged DNA through a
non-specific DNA binding domain (amino acids 363-393) [32-36].

Under unstressed conditions, the expression level of p53 is very low in most tissues
because of a short protein half-life [37]. In the immortalized mouse 308 keratinocyte cell
line, the half-life of wild-type (WT) p53 is only about 16 min [38]. At the physiological
temperature of 37°C, WT p53 is highly unstructured (more than 50% unfolded) and
shows low DNA-binding ability (75% loss after incubation) [39]. Several
posttranslational mechanisms, such as phosphorylation, acetylation and sumoylation,
contribute in great measure to the stabilization and activation of p53 (reviewed in [37]).
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II.B. Types of DNA damage

DNA damage is the best known cause of p53 activation. DNA damage can be initiated by
a number of endogenous (such as ROS) and exogenous (such as UV, radiation and
chemicals) stimulations. Common types of DNA damage include covalent modification
of bases (e.g., oxidation, alkylation and hydrolysis, Fig. 1), mismatch of bases (Fig. 2),
breaks in the backbone occurring on one or both of the DNA strands, and crosslinks
between bases on the same or opposite DNA strand and between DNA and protein
molecules.

II.C. ROS and their reactions with DNA bases and proteins

Excessive ROS oxidizes DNA bases by means of breaking strands and modifying bases
and nucleotides. The interaction of ROS and DNA varies according to type. Singlet
oxygen ( 1 O 2 ) oxidizes guanine, yielding two 4R* and 4S* diastereomers of
4,8-dihydro-4-hydroxy-8-oxo-2'-deoxyguanosine as the main product when the
guaninemoiety is oxidized within nucleosides, and 7,8-dihydro-8-oxoguanine as the main
product when the oxidation occurs in double-stranded DNA [40]. ·OH is extremely
unstable and easily attacks other molecules (usually at double bonds) because an unpaired
electron exists in its outermost shell of electrons, resulting in the addition of a hydroxyl
group. In addition, ·OH may remove a hydrogen atom from a carbon atom to form a H2O
molecule, leaving an unpaired atom on the carbon atom. When a molecule is attacked
by ·OH, it becomes a radical and can initiate a chain reaction by subsequently changing
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Figure 2. An example of DNA base mismatch. A. Normally, adenine (A) pairs with
thymine (T) by two hydrogen bonds (dash line) and cytosine (C) pairs with guanine (G)
by three hydrogen bonds. B. A and C undergo an amine-imine tautomerization, and T and
G undergo an amide-iminol tautomerization. The tautomers are designated A*, C*, T*
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mismatches.
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another molecule into a radical, until the two radicals use their unpaired electrons to form
a covalent bond (Fig. 3). A unique property of ·OH is that it can react with all four kinds
of DNA bases, yielding a variety of products [41] (Fig. 4). Although O2·− is both an ion
and a radical, and thus is supposedly highly unstable, it cannot interact with DNA directly
at physiological levels, probably due to its relatively weak reactivity and poor solubility
in aqueous solution, which is also the case for H2O2. However, the addition of H2O2 to
cells does cause DNA damage, possibly because H2O2 is converted to ·OH within nuclei
by Fenton reactions [42]. Researchers have established patterns of DNA damage induced
by some reactive species. Therefore, the reactive species causing the damage may be
determined from the type of base damage [41].

ROS can also react with proteins. Most amino acids can be modified by endogenous ROS,
and cysteine, methionine and tyrosine are the common residues modified by ·OH, O2·−
and HOCl [43]. Upon oxidation, the sulfhydryl group (-SH) on cysteine can be converted
to a sulfenic group (-SOH), which can then react with thiols or be further oxidized to
sulfinic (-SO2H) and sulfonic (-SO3H) groups [44]. Another result of -SH oxidation is
theformation of disulfide bonds (-S-S-). However, they can be easily reduced to -SH by
antioxidative enzymes such as thioredoxin [45]. When oxidized, methionine
residuesundergo a pathway different from that of cysteine. Methionine is converted to
methionine sulfoxide (containing an -SO- group) and methionine sulfone (containing an
-SO2- group) if further oxidized [46]. The process of conversion from cysteine sulfenic
acid to sulfinic acid and sulfonic acid is irreversible, but the oxidation of methionine can
be reversed by methionine sulfoxide reductase A (MSRA), an NADH-dependent enzyme
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that reduces methionine-R-sulfoxide to methionine [46] or selenoprotein R that reduces
the S stereoisomer of methionine sulfoxide [47]. MSRA has been shown to be an
antioxidant defense regulator protecting against oxidative damage in mouse and
drosophila models [48, 49]. The aromatic amino acid residue phenylalanine can be
oxidized by ·OH, yielding tyrosine. Tyrosine residues can be modified by HOCl and
other oxidants, which cause their conversion to a series of products, including
o,o’-dityrosine, 3,4-dihydroxyphenylalanine, 3-nitrotyrosine, and 3-chlorotyrosine [43,
50]. In addition to interacting with individual residues, ROS can directly damage the
peptide backbone of proteins, resulting in the generation of protein carbonyls.

Redox signaling is the concept that free radicals, ROS, and other electronically activated
species act as messengers in a biological system. ROS-protein interaction plays a key role
in redox signaling. The primary effect of ROS in its capacity as a signal transduction
messenger is the reversible oxidation of protein residues. By regulating the redox status
of target proteins, ROS participate in a variety of signaling pathways. Examples of
ROS-regulated proteins playing parts in signal transduction include transcription factors,
protein tyrosine kinases (PTKs), and protein tyrosine phosphatases (PTPs) [51-60].

III. p53, ROS and redox proteins

It has long been suggested that ROS are downstream mediators of p53-dependent
apoptosis [61, 62]. The work that provided convincing evidence used transgenic human
and rat smooth muscle cells [63]. The researchers showed that, concomitantly with
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increasing levels of p53 and onset of apoptosis, overexpression of p53 upregulates ROS
levels in human smooth muscle cells, which are susceptible to p53-induced apoptosis.
However, similar effects were not observed in rat smooth muscle cells, which are
resistant to p53-induced apoptosis, although similar p53 levels were observed in the two
cell lines. The genetic mechanism underlying the ROS regulation of p53 was
subsequently elucidated. It was predicted that many genes induced by p53 expression
before the onset of apoptosis encoded proteins that could generate or respond to oxidative
stress [64]. The discovery confirmed a significant role of ROS in p53-induced apoptosis
and indicated a possibility that p53 induces ROS production by transcriptionally
activating various redox-related genes. A three-step model for p53-induced apoptosis was
proposed: (i) the transcriptional induction of redox-related genes; (ii) the formation of
ROS; and (iii) the oxidative degradation of mitochondrial components, culminating in
cell death [64]. This model was later supported in human epithelial breast cancer MCF7
cells by a study using copper and zinc as ROS inducers [65]. In the following sections,
several p53 targets related to oxidative stress are discussed.

III.A. p53-induced gene 3 (PIG3)

Polyak et al. transfected a replication-defective adenovirus encoding p53 (Ad-p53) into
colorectal cancer cell line DLD-1 containing an inactive endogenous p53 gene. The
patterns of gene expression were then analyzed, and a series of upregulated genes that
followed p53 expression was revealed. These genes were named PIGs (p53-induced
genes) and their functions were inferred. Interestingly, many PIGs members have a link
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with oxidative stress (Table 1) [64]. Expression of PIG3 was shown to be correlated with
the generation of ROS in the cell. The PIG3 gene is located on chromosome 2 (2p23.3)
and includes 4 exons. The PIG3 promoter can be transactivated by WT p53 but not
mutant p53. PIG3 expression in the absence of cellular stress is not sufficient to inhibit
cell growth or induce apoptosis, but a role for PIG3 in p53-mediated apoptosis cannot be
ruled out, because a p53-mediated elevation of PIG3 was observed after treating cells
with the pro-apoptotic anthracycline quinone, adriamycin [66]. NAD(P)H quinone
oxidoreductase 1 (NQO1), with which PIG3 shares sequence homology [64], was
established as the catalyst of bioactivation of antitumor quinones [67-70]. Taken together,
these findings suggested that PIG3 expression plays a role in increasing bioactivation of
quinones, resulting in ROS production and apoptosis.

The mechanisms of how p53 regulates PIG3 expression were then studied in detail.
Venot et al. reported that the proline-rich domain (see section I.A.) is necessary for PIG3
gene transactivation. This domain does not transactivate several promoters, such as
WAF1, mdm-2 and BAX, but is responsible particularly for ROS production and
sequence-specific transactivation of the PIG3 gene [27]. However, transactivation of the
PIG3 gene by p53 seems not to follow ordinary mechanisms. Szak et al. demonstrated
that p53 had a lower affinity for the consensus binding site in the PIG3 promoters
compared to its counterparts in the p21 and mdm-2 genes, suggesting additional factors
were required to stabilize the interaction of p53 with the PIG3 promoter [71]. Another
group provided a possible explanation by showing that p53 does not interact with a p53
consensus binding site but with a pentanucleotide microsatellite sequence within the
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Table 1. p53-induced genes (PIGs) (after [64])

Gene Name

Function/homology

Notes

p21

CDK inhibitor

PIG1*

Galectin-7

PIG2

Guanidinoacetate N-methyl transferase

PIG3*

Quinone oxidoreductase homologue

PIG4*

Serum amyloid A

PIG5

Normal keratinocyte mRNA

PIG6*

Proline oxidase homologue

PIG7*

TNF-α induced mRNA

TNF-α is an inducer of
oxidative stress.

PIG8*

Etoposide-induced mRNA

Etoposide is a quinone
known to generate ROS.

PIG9

Tax1-binding protein

PIG10

Actin-binding protein

PIG11*

Sensitizes cells to arsenic-trioxide-induced
apoptosis, a process in which ROS are also
involved [72, 73].

PIG12*

Microsomal
homologue

PIG13

Unknown

Members of the galectin
gene family can stimulate
superoxide production.

Can be induced by
oxidative stress.

glutathione

transferase

*: Genes that have a link with oxidative stress
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PIG3 promoter to activate the promoter [74]. The microsatellite is polymorphic, with a
varying number of pentanucleotide repeats directly correlated with the extent of
transcriptional activation by p53. Supporting the existence of interaction between the p53
protein and the microsatellite, it has been suggested that the microsatellite polymorphism
may be associated with a differential susceptibility to cancer [74].

III.B. Redox proteins as p53 targets

Some other genes involved in intracellular ROS regulation were subsequently identified
as p53 target genes. Glutathione peroxidase (GPX) is a primary antioxidant enzyme
family catalyzing the reduction of hydroperoxides to their corresponding alcohols and the
conversion of free H2O2 to water, which are accompanied by the oxidation of glutathione
(GSH). Members of the GPX family include GPX1, GPX2 (gastrointestinal), GPX3
(plasma), GPX4 (phospholipid hydroperoxidase), GPX5 (epididymal androgen-related
protein), GPX6 (olfactory) and GPX7 (also olfactory). The promoter of the GPX1 gene
was found to be transactivated by endogenous WT p53 activated by etoposide, a
topoisomerase II inhibitor and a p53 activator [75]. The relationship between p53 and
mitochondrial enzyme manganese superoxide dismutase (MnSOD), a significant ROS
scavenger inside mitochondria, is an interesting one. On one hand, MnSOD is subject to
p53-mediated transcriptional repression at the promoter level; on the other hand, MnSOD
overexpression decreases p53-gene expression at the promoter level [76]. Catalase (CAT),
another antioxidative enzyme catalyzing the decomposition of H2O2 into H2O and O2,
does not, however, increase upon p53 activation, while CAT overexpression inhibits
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p53-mediated apoptosis [77]. Mitochondrial ferredoxin reductase (FR) is a mitochondrial
flavoprotein that initiates electron transport to cytochrome P450 from NADPH and also
contributes to tumor growth suppression and cell viability. The gene (FDXR) encoding
FR is significantly induced by p53 in human colon cancer cells treated with
5-fluorouracil (5-FU), an effective adjuvant therapy for patients with colon cancer and a
potent apoptosis inducer [78]. Triphenylmethyl phosphonium (TPMP)-vitamin E
(MitoVitE) and TPMP-ubiquinol (MitoQ), two antioxidants specifically targeted to
mitochondria, completely prevent 5-FU-induced apoptosis, whereas their non-targeted
counterparts are inactive, indicating that 5-FU induced apoptosis is dependent on ROS
generation [78].

A recent report indicated that a common mechanism of p53 regulation on antioxidant
responsive

genes

is

that

p53

directly

suppresses

the

NF-E2-related

factor

(Nrf2)-dependent transcription of antioxidant response element (ARE)-containing
promoters, which can be triggered by DNA damage [79]. Examples of genes regulated by
p53 through this mechanism include x-CT (a subunit of the cystine/glutamate transporter),
glutathione S-transferases (GSTs), and NADH quinone oxidoreductase 1 (NQO1) [79].

III.C. Interaction between PTEN and PIG3

The phosphatase with tensin homology PTEN is a lipid phosphatase that negatively
regulates the phosphatidylinositol 3-kinase (PI3K) pathway [80]. By counteracting the
PI3K pathway, which is a potent stimulator of cell proliferation and survival, PTEN acts
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as a tumor suppressor. Moreover, the PI3K pathway sits at the junction of several other
important tumorigenic signaling pathways (reviewed in [81]). Like p53, inactivating
mutations of the PTEN gene are found in a wide range of common human cancers
[82-84]. Interestingly, just opposite p53, PTEN deletion upregulates PIG3 alongside
several other p53 effectors [85]. Given the fact that p53 transactivates PTEN [86], how
PIG3 expression is balanced between p53 and PTEN regulation is a topic needing further
elucidation.

IV. Events downstream of ROS

What happened after p53 induction of ROS? An obvious consequence was apoptosis, but
the exact mechanisms remained unclear. The work by Li et al. suggested that
mitochondria played a role. Using HeLa cells, they showed that, after p53 induction of
ROS, the mitochondrial membrane potential (ΔΨm) increases, activating the caspase
cascade [87]. Downstream of caspase activation, ΔΨm decreases, and the alternation of
ΔΨm induced by p53 can be prevented by Bcl-2 downstream of ROS [87]. Cytochrome c
is not involved in this model of p53-induced apoptosis [87]. ROS were then established
to be mediators of senescence, and a rise in intracellular ROS may be an important signal
that triggers senescence (reviewed in [88, 89]). Mitochondrial permeability transition
pore (MPTP) is a mitochondrial protein complex assembled at contact sites between the
inner and outer membranes. Because MPTP was suggested to be a key determinant of the
severity of mitochondria-mediated apoptosis [90], the interaction between permeability
transition and p53 became a hot research subject. Various studies suggested that, upon
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various kinds of stimulation related to p53, permeability transition inhibitor cyclosporin
A blocks ROS generation [91], increases ΔΨm [91], releases cytochrome c into cytosol
[91-93] and induces DNA fragmentation [94], but does not block caspase activation [95].
These data validate the roles of ROS and MPTP in p53-mediated pathways.

V. Regulation of p53 by redox system components

Given the multiple ways p53 may regulate ROS levels and redox protein expression, it is
of great interest whether these components of the redox system have regulatory effects on
p53. This section is a summary of some notable research addressing the effects of ROS
and redox proteins on p53.

V.A. Effects of ROS on p53

Similar to many positive and negative feedback loops in p53 signaling pathways
involving multiple proteins (reviewed in [96]), ROS can regulate p53 through many
pathways, and significant evidence supports this hypothesis. First, ROS-treated cells
show increased p53 stability and activity. In human umbilical vein endothelial cells, H2O2
was shown to induce p53 phosphorylation, which required transactivation of
platelet-derived growth factor-β receptor and subsequent ataxia telangiectasia mutated
kinase activation [97]. H2O2-treated human hepatoma cells demonstrate increased
apoptosis [98] and p53 mutation in a specific exon [99]. ROS are required for p53
activation in leukemia cells and normal lymphocytes [100] and stabilization of p53
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during hypoxia in mammary breast cancer cells MCF-7 [101]. Second, cells lacking
antioxidant defense demonstrate increased p53 expression. In human lung cancer cells in
which peroxiredoxin (Prx) I activity was lowered, ROS increased, upregulating p53
expression [102]. Similarly, in human B lymphoma cells treated with L-buthionine
sulphoximine, an inhibitor of γ-glutamyl cysteine synthetase which is essential in
gluathione biosynthesis, a truncated form of p53 is expressed after ROS production
increases [103]. Third, antioxidants inhibit p53 activity. Two potent antioxidants,
N-acetyl-cysteine and glutathione, strongly suppressed p53-mediated apoptosis in human
hepatoma cells [104]. Fourth, there are reports that suggest that nuclear factor-kappa B
(NF-κB) [105] and Fas [99, 106] play a role in ROS regulation of p53, but some other
evidence suggests that ROS and p53 may not be required for Fas-induced apoptosis [107,
108]. The source of stress may be the key determinant of which pathway is involved [107,
108]. In summary, ROS may have a positive feedback effect on p53 expression and
activation, but the detailed mechanisms have not been clarified yet.

V.B. Redox proteins regulate p53 activity

V.B.1. WOX1

The genomic organization patterns of human and murine WW domain-containing
oxidoreductase (WOX1) are almost identical [109]. The human WOX1 gene encodes a
protein that contains two WW domains responsible for protein-protein interactions and a
short-chain dehydrogenase (SDR) domain. It has been suggested that WOX1 is involved
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in sex steroid metabolism and signaling pathways [110, 111]. This gene has been
reported to behave as a suppressor of tumor growth in human breast and prostate, and in
ovarian, oral squamous, pancreatic and hepatocellular cell lines [111-118]. Murine
WOX1 was shown to enhance TNF cytotoxicity in L929 cells by downregulating
apoptosis inhibitors Bcl-2 and Bcl-xL and upregulating pro-apoptotic p53 by the ADH
domain [119]. Specifically, Tyr33-phosphorylated WOX1 directly binds and stabilizes
Ser46-phosphorylated p53 [120].

V.B.2. NQO1

NQO1 is a flavin adenine dinucleotide (FAD)-binding protein that forms homodimers
and reduces quinones to hydroquinones. The protein's enzymatic activity prevents the one
electron reduction of quinones that results in the production of radical species. It has been
demonstrated that NQO1 stabilizes hot-spot p53 mutant proteins in cancer [121]. This
role of NQO-1 was further confirmed by an in vivo study that suggests that the sensitivity
of NQO1-null mice to benzo(a)pyrene-induced skin cancer is increased due to lower
induction of p53 and decreased apoptosis [122].

V.B.3. Ref1

Another gene drawing much attention is redox factor-1 (Ref1). The Ref1 protein is both a
regulator of the redox state of a number of proteins and a DNA repair (A/P) endonuclease
[123]. It functions in the process of base excision repair (BER) to cleave DNA 5' to
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abasic sites, as well as to load DNA polymerase γ onto DNA [124]. The redox activity of
Ref1 is mediated by ROS and protein kinase C (PKC) phosphorylation in response to
DNA damaging agents such as oxidizing agent hypochlorite [125]. PKC had been known
to phosphorylate p53 [126, 127] and thus increase p53 activity in cell cycle control,
particularly the induction of the G1/S growth arrest [128, 129].

There is some evidence demonstrating that Ref1 is able to stimulate p53 activity. While
Refl was observed to repair inactivated (oxidized) forms of both full-length and
carboxy-terminally truncated p53, it potently stimulated full-length but not truncated p53
in the presence of reducing agents in vitro and in vivo [123]. Consistent with this,
reduction of residues Cys275 and Cys277 of p53 by selenomethionine (the major dietary
source of selenium) caused p53 to recruit Ref1 and activate DNA-repair machinery,
suggesting that Ref1 is required in the activation of p53 by selenomethionine [130]. An in
vivo study further revealed that Ref1 enhances the ability of p53 as a transcription factor
and an apoptosis inducer [131]. Interestingly, Ref1 and thioredoxin reductase cooperate
in the regulation of basal p53 activity, but not in p53 induction by DNA damage [132].

V.B.4. Azurin

Azurin is a redox protein involved in a series of electron-transfer reactions with
cytochrome C551 and nitrite reductase [133]. Found to be localized in the cytosol and the
nuclear fractions, azurin was determined to induce apoptosis in J774 murine macrophages
through complex formation and stabilization of p53 and ROS generation [134]. In human
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cancer (melanoma UISO-Mel-2) cells, azurin forms a complex with p53, thereby
stabilizing it and raising its intracellular levels, and hence apoptosis is triggered through
the mitochondrial pathway [135]. A redox-negative mutant form of azurin (M44K/M64E)
demonstrates much less cytotoxicity, fails to form a complex with p53 and shows less
efficiency in stabilizing p53 than WT azurin, suggesting that the functional site of azurin
involved in p53 regulation might be at those two amino acid residues [135]. The same
group later confirmed that the M44/M64 residues are responsible for p53 regulation by
showing that WT and M44K/M64E mutant azurin contradictorily affect p53 function
[136]. The former induces apoptosis but minimally inhibits cell-cycle progression,
whereas the latter is incapable of inducing apoptosis but mediates strong inhibition of
cell-cycle progression [136].

A good example of a p53-binding protein is mdm2 [137]. The mdm2-p53 interaction has
been extensively studied (reviewed in [138]). Briefly, the hydrophobic residues of Phe19,
Trp23 and Leu26 of the transactivation domain of p53 bind a deep hydrophobic binding
pocket on the mdm-2 surface, forming an amphiphilic α-helix (literature cited in [138]).
A comparison of the mechanisms shows how the interaction of the redox proteins
mentioned above and mdm2 with p53 may be beneficial. Studies of this aspect of NQO1
have been extensive. NQO1 does not inhibit p53 degradation mediated by mdm-2 [139],
but hsp90 stabilizes mutant p53 by inhibiting mdm-2 [140]. NQO1 keeps p53 from
proteasomal degradation through an mdm-2 and ubiquitin-independent mechanism [141].
Accordingly, NQO1 does not associate with mdm-2 co-immunoprecipitated with p53
[142]. Also, an inhibitor of NQO1, dicoumarol, is more effective in decreasing WT p53
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levels and apoptosis in normal thymocytes than hsp90 inhibitors are, which performs
better in myeloid leukemic cells [139]. These findings suggest that NQO1 stabilizes p53
through a distinct pathway, particularly in response to oxidative stress [139]. Ref1
regulates p53 by promoting p53 tetramerization in two ways, thereby enhancing p53
binding to target DNA [143]. First, Ref1 increases the association of p53 dimers into
tetramers, the optimized form for p53 activity [143, 144]. Second, Ref1 contributes to the
de-stacking of higher oligomeric forms of p53 into the tetrameric form in vitro [143]. For
the other two proteins, the detailed mechanisms remain unclear, even though the amino
acid residues by which WOX1 and azurin interact with p53 have been identified.

VI. An antioxidative function of p53

It was surprising that p53 was found to have an antioxidative function. Although it has
been reported that p53 activates GPX [75], it could be argued that GPX induction and
ROS generation occur at different time points dowstream of p53 activation, with ROS
generation

occurring

later

[145].

Aldehyde

dehydrogenase

4

(ALDH4),

a

mitochondrial-matrix NAD+-dependent enzyme that catalyzes the second step of the
proline degradation pathway [146], was found to be directly transactivated by p53 [147].
ALDH4 appears to be an antioxidative protein, because human lung carcinoma H1299
cells transformed to overexpress ALDH4 showed significantly lower intracellular ROS
than control cells after H2O2 or UV treatment [147]. The sestrin gene family is another
antioxidative protein family revealed to be a p53 target. In an attempt to use cDNA
microarray in order to identify novel genes participating in cellular responses to
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prolonged hypoxia in cancer cells, the gene designated Hi95 was found to be
p53-inducible in human glioblastoma cell line A172 and to prevent apoptosis induced by
ischemia or H2O2 in human breast carcinoma cell line MCF7-tet-off [148]. Later, Hi95
was put into the sestrin gene family [149]. The antioxidative role of sestrins was
confirmed by evidence demonstrating that after a peroxide burst, sestrins substantially
increase the rate of recovery of overoxidized Prxs [150].

This leads to the question of how prooxidants and antioxidants regulate p53. A promising
answer has been given by Sablina et al. [151]. By examining the response of p53 under
different severities of oxidative stress, they showed that p53 decreases ROS after mild
stress (0.2 mM H2O2) but increases ROS after grave stress (1 mM H2O2). Antioxidant
genes SESN2, SESN1 and GPX1 were rapidly activated by p53 at both low and high
concentrations of H2O2 (<0.2 h and <2 h, respectively), while prooxidant genes TP53I3
and BBC3 were activated more slowly (>0.4 h at low H2O2 concentration and >6 h at
high H2O2 concentration). The researchers suggest that whether p53 is inclined to yield
antioxidative or prooxidative effects depends on the stress condition. In stress-induced
apoptosis, p53 functions as a prooxidant, resulting in release of mitochondrial ROS. In
non-stressed or physiologically stressed cells, the antioxidant function of p53 is mediated
through a set of antioxidant gene products, which are responsive to lower levels of p53.
Under mild conditions, the antioxidant function of p53 decreases the probability of
genetic alterations and assists the survival and repair of cells in a nonfatal way, without
triggering the apoptotic pathway. The phenomena described by Tan et al. [75], that p53
quickly upregulates GPX expression, agrees with this model.
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However, it is hard to distinguish a benign stress condition from a devastating one. First,
it is difficult to determine real-time ROS concentration in living cells. As Nicholls and
Budd have pointed out [152], major impediments include the rapidness and complexity of
intracellular ROS production and conversion, non-quantitative assays due to competition
between dyes and redox enzymes, and non-specific fluorescent ROS probes which may
respond to other biochemical changes such as pH and ΔΨm. However, this issue will
hopefully be partially resolved by the emergence of new probes capable of accurately
detecting natural signaling levels of H2O2 generated by living cells [153]. Second, it is
still under debate whether exogenous addition of ROS (commonly H2O2) can mimic an
actual physiological or pathophysiological condition. Given the difficulty in measuring
real-time ROS levels, it is hard to estimate how much ROS should be added. Therefore,
results of current studies utilizing exogenous ROS are sometimes questioned, although
some evidence suggests that H2O2 in signaling pathways may be produced exogenously
under biological conditions [154]. Finally, experiments employing known concentrations
of ROS yield puzzling results. Some reports, previously cited, show that 1-6 h treatment
with 0.1-0.2 mM H2O2 effectively induces apoptosis [97-99, 146], while in another
research project significant apoptosis onset was not observed under similar treatment
[151]. While cells may have different sensitivities to oxidative stress, a concentration
“threshold” of H2O2 to induce the antioxidative effect of p53 without initiating the
p53-induced apoptotic pathway might not exist. Under mild conditions, mitochondrial
apoptosis may still progress, and the progression seems to become apparent as treatment
time lengthens or oxidant concentration increases. Whether and to what extent p53 can
counteract the apoptotic trend in various cell types are questions demanding further
research.
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VII. ROS levels: a change in the faces of p53?

A more generic question than the ability of ROS to choose between antioxidant and
prooxidant functions of p53 is whether ROS levels can decide cell fate through p53. To
address this question, a summary of some related p53 functions and characteristics is
necessary.

p53 is always called “the guardian of the genome.” not only because it is extremely
sensitive to DNA damage [155], but also because it interacts with a variety of DNA
double-strand break sensing and repair proteins and it can serve as a 3'-5' exonuclease
[25]. A recent report suggested that p53 may even contribute to mitochondrial DNA
(mtDNA) repair by interacting with DNA polymerase γ [156]. The stability of both
nuclear and mitochondrial DNA leads to cell survival.

A small fraction of p53 has been proved to translocate to mitochondria at the onset of
p53-dependent apoptosis [157]. The primary signal that causes localization of p53 to
mitochondria is mitochondrial ROS generation, which preferentially induces oxidative
mitochondrial DNA damage [156]. Mitochondria-translocated p53 can trigger
transcription-independent apoptosis by direct suppression of the antiapoptotic Bcl-xL and
Bcl2 proteins [158] and activation of the proapoptotic Bax [159, 160] and Bak [161].
Mitochondrial p53 accumulation happens soon after stress stimulation, and before its
transcriptional effect [162]. In accordance with this, mitochondrial p53 translocation
occurs before the nuclear translocation of p53, and p53 targets MnSOD and directly
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inhibits MnSOD activity when translocating to mitochondria, indicating a novel pathway
by which p53 regulates ROS levels [163]. Some efforts have been made to find the force
that drives p53, normally localized in the nucleus, to mitochondria. Loss of Bax
completely protects human colon carcinoma cells (HCT116) against p53-induced,
transcription-independent apoptosis, and reexpression of Bax restores p53 sensitivity in
HCT116 cells, indicating that Bax may be able to bring p53 to mitochondria [159]. Bad, a
positive regulator of cell death which can be transactivated by p53, can also direct
nucleus-localized p53 to the mitochondria and form a complex with p53 there, promoting
apoptosis via activation and oligomerization of Bak [164]. Endogenous p53 was found to
be cleaved by caspases (specifically, caspase-3, -6, and -7, but not caspase-8) during
apoptosis induced by several anticancer drugs, and some caspase-cleaved p53 fragments
localized to mitochondria [165]. Since caspase activation has been well documented as a
marker of the apoptosis process, this finding suggests a positive feedback loop in
p53-induced apoptosis. Details on how p53 translocates to mitochondria and what other
functions mitochondria-localized p53 possesses are attractive topics.

The discovery of two new p53 targets has revealed another unexpected aspect of p53
function, the ability to regulate glucose metabolism. In a study to provide a genetic
explanation of the Warburg effect (that cancer cells preferentially utilize glycolytic
pathways for energy generation while down-regulating their aerobic respiratory activity
[166]), synthesis of the cytochrome c oxidase 2 (SCO2) gene, whose translational product
is a critical regulator of the cytochrome c oxidase complex (also known as Complex IV),
which is the major site of oxygen utilization in the eukaryotic cell, was shown to be
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p53-transactivated [167]. It was demonstrated that a p53-induced gene, TP53-induced
glycolysis and apoptosis regulator (TIGAR), controlled glucose metabolism through the
pentose phosphate pathway by lowering fructose-2,6-bisphosphate levels in cells,
resulting in an inhibition of glycolysis and an overall decrease in intracellular ROS levels
[168]. These studies reveal that inhibition of glycolysis, the dominant way cancer cells
generate power to sustain themselves, is a new weapon for tumor suppression by p53. It
should be noticed that AMP-activated protein kinase (AMPK) induces p53
phosphorylation [169] on Ser15 [170] and results in cell cycle arrest [170, 171],
suggesting that metabolic status has a reverse impact on p53.

The answer to how ROS can affect these issues may again be that physiological and
cytotoxic ROS levels will lead p53 to different pathways. Once stimulation causes ROS
concentrations to become abnormally high but not critical, p53 may first try to repair
nuclear and mitochondrial DNA and transactivate antioxidant enzymes to counteract
increased ROS production. However, if ROS levels continue to rise, p53 may turn into a
killer by inducing apoptosis through both mitochondrial and nuclear pathways. A recent
report described how different levels of ROS result in different cell fates, using bladder
(EJ) and prostate (PC3) tumor cell lines as examples [172]. When a small increase of p53
levels was induced, cells showed characteristics of senescence with a small increase in
ROS levels. However, with a large increase in p53 levels, cells demonstrated apoptosis
accompanied by a greater increase in ROS levels. Moreover, addition of exogenous ROS
could convert a senescent response induced by relatively low levels of p53 into apoptosis.
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Related events occurring in ROS regulation of cell fate mediated by p53 are summarized
in Fig. 5.

VIII. Concluding Remarks

While ROS have long been established as a mediator of p53-induced apoptosis, recent
research projects have revealed the impact of ROS on p53. ROS levels have been proven
to regulate the redox functions of p53, and to have the potential of determining cell fate
through p53. Nonetheless, there are still many unanswered questions, some of which
follow.

1. Are there thresholds of ROS levels and/or stimulation time length for p53 to switch
from functioning to sustain cell survival to triggering apoptosis? More generally, is there
a clear line between physiological and toxic ROS levels?

2. If a clear line exists, what are the thresholds in different types of cells and how do
characteristics of specific cells influence the thresholds? If there are no clear boundaries
between physiological and toxic ROS levels, how do cells choose their fate under various
conditions?

3. More and more new unanticipated properties of p53 have been discovered. For
example, literature suggests that for p21, PIG3 and Bax, p53 demonstrates a hierarchy in
its transactivation activity and subsequent pathway activation by preferentially
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redox proteins
(WOX1, NQO1, Ref1, azurin)
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result in cancer: tumor suppression
result in normal tissue: injury

severe, cytotoxic stress
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SCO2 and TIGAR

p53

inhibition of
glycolysis

mitochondrial
translocation
nuclear
translocation

transactivates antioxidant enzymes
(GPX, ALDH4, SESN 1 & 2)

p53 cleavage

MnSOD, Bcl2 and Bcl-xL

apoptosis

Bax, Bak and Bad
caspase activation

?
ROS ↑

ROS ↓

cell survival

transactivates prooxidative
proteins (PIG3)
transcriptionally inhibits
antioxidative proteins (MnSOD)

cytochrome c release

p53 ↑

transactivates proapoptotic proteins
(Bax, Bak, Bad, NOXA, PUMA, p53AP1, etc.)

mitochondrial dysfunction
(ΔΨ m ↑, MPTP opening)

Figure 5. Proposed network of ROS regulation on cell fate through p53. Different colors
of arrows indicate different pathways. Blue arrow: Some redox proteins contribute to the
stabilization of p53. Green arrows: Under physiological ROS levels, oxidative stress is
mild. p53 transactivates antioxidant enzymes, resulting in lower ROS levels and cell
survival. Black arrows: Under high ROS levels, oxidative stress is cytotoxic. p53
translocates to mitochondria first. In the mitochondria, p53 directly inhibits MnSOD,
Bcl2 and Bcl-xL and activates Bax, Bak and Bad. These events lead to ROS increase and
cytochrome c release which trigger caspase cascade and apoptosis. p53 later translocates
to the nucleus, where it transactivates prooxidative proteins and transcriptionally inhibits
antioxidative proteins, inducing more ROS increase. The ROS increase may upregulate
p53 furthermore, thus the positive feedback loop. More p53 results in transactivation of
multiple proapoptotic proteins, which cause mitochondrial dysfunction. The
mitochondrial apoptosis pathway is then initiated. Downstream of cytochrome c release,
caspase activation brings about p53 fragments, parts of which are found to translocate to
the mitochondria. Whether ROS increase contributes to the nuclear translocation of p53
remains undetermined. Red arrows: p53 can inhibit glycolysis by transactivation of
SCO2 and TIGAR. The final effects of pathways indicated by black and red arrows
pathways are tumor suppression if the pathways take place in cancer cells, and tissue
injury if the pathways happen in normal cells.
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transactivating p21 over the other two [173-175]. What additional functions may the
tumor suppressor have? How are they regulated?

ROS, the inevitable byproduct of the oxidative phosphorylation process, may be able to
do more than what is currently known. Further research of the regulatory function of
ROS on p53 will contribute to a greater understanding of mechanisms that regulate cell
fate as well as to developing therapies for cancer.
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